Literature DB >> 25520857

Methylation-associated silencing of MicroRNA-335 contributes tumor cell invasion and migration by interacting with RASA1 in gastric cancer.

Zhengrong Li1, Daojiang Li1, Guoyang Zhang1, Jianbo Xiong2, Zhigang Jie1, Heping Cheng3, Yi Cao1, Mengmeng Jiang1, Liangqing Lin1, Zhibiao Le1, Shengxing Tan1, Wenyu Zou2, Binbin Gong2, Shengrong Lin2, Ke Yang2.   

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs that function as endogenous silencers of target genes, previous studies have shown that miR-335 play an important role in suppressing metastasis and migration in human cancer including gastric cancer (GC). However, the mechanisms which result in aberrant expression of miR-335 in GC are still unknown. Recent studies have shown that the silencing of some miRNAs is associated with DNA hypermethylation. In this study, we find the promoter of miR-335 we embedded in CpG island by accessing to bioinformatics data and the low expression of miR-335 in 5 gastric cell lines can be restored by 5-aza-2'-deoxycytidine (5-Aza-dC) treatment. So we postulated that the miR-335 genes undergo epigenetic inactivation in GC. Subsequently, in GC cells and tissues, we performed quantitative real-time PCR (RTQ-PCR) to assess the expression of miR-335, and methylation-specific PCR (MSP) and bisulfite sequence-PCR (BSP) to evaluate the DNA methylation status in the CpG islands upstream of MiR-335. The result showed that the expression of miR-335 was significantly reduce in gastric cancer cell lines and tumor tissues compared to matched normal gastric tissues, and cell lines, and which is inverse correlation with DNA hypermethylation of miR-335 both in GC cells lines and tissues, but not in normal tissues. In addition, we found that the lower miR-335 expression induced by abnormal methylation may be mainly involved in gastric cell invasion and metastasis in GC tissues. No statistical significance was found about miR-335 expression and methylation level between healthy individuals with and without H. pylori (HP) infection. Finally, we carry out miRNA transfection, RTQ-PCR and western blot assay to find the RAS p21 protein activator (GTPase activating protein) 1 (RASA1) may be the possible target genes which lead to the gastric cell invasion and metastasis, furthermore, the re-expression of endogenous miR-335 by 5-Aza-dC treatment can exert effects similar to exogenous miRNAs transfection. Taken together, our results suggest that miR-335 may be silenced by promoter hypermethylation and play important roles in gastric cell invasion and metastasis through its target genes, such as RASA1. Its methylation level might be a predictive epigenetic marker of GC and remodeling on the expression by demethylation can provided a potential therapeutic strategy.

Entities:  

Keywords:  Cancer metastasis; MiR-335; RASA1; cancer invasion; gastric carcinoma; methylation

Year:  2014        PMID: 25520857      PMCID: PMC4266701     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  42 in total

1.  Promoter2.0: for the recognition of PolII promoter sequences.

Authors:  S Knudsen
Journal:  Bioinformatics       Date:  1999-05       Impact factor: 6.937

Review 2.  MicroRNAs (miRNAs) in cancer invasion and metastasis: therapeutic approaches based on metastasis-related miRNAs.

Authors:  Achim Aigner
Journal:  J Mol Med (Berl)       Date:  2011-01-14       Impact factor: 4.599

Review 3.  MicroRNAs in biological processes and carcinogenesis.

Authors:  Hirotaka Osada; Takashi Takahashi
Journal:  Carcinogenesis       Date:  2006-10-06       Impact factor: 4.944

Review 4.  Metastasis-related miRNAs, active players in breast cancer invasion, and metastasis.

Authors:  Ming Shi; Dan Liu; Huijun Duan; Beifen Shen; Ning Guo
Journal:  Cancer Metastasis Rev       Date:  2010-12       Impact factor: 9.264

Review 5.  Epigenetic changes in cancer.

Authors:  Kirsten Grønbaek; Christoffer Hother; Peter A Jones
Journal:  APMIS       Date:  2007-10       Impact factor: 3.205

6.  A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation.

Authors:  Jharna Datta; Kalpana Ghoshal; William A Denny; Swarna A Gamage; Darby G Brooke; Pasit Phiasivongsa; Sanjeev Redkar; Samson T Jacob
Journal:  Cancer Res       Date:  2009-05-05       Impact factor: 12.701

7.  miR-335 suppresses migration and invasion by targeting ROCK1 in osteosarcoma cells.

Authors:  Yong Wang; Wei Zhao; Qin Fu
Journal:  Mol Cell Biochem       Date:  2013-08-22       Impact factor: 3.396

8.  Identification of hsa-miR-335 as a prognostic signature in gastric cancer.

Authors:  Zhi Yan; Yimin Xiong; Weitian Xu; Juan Gao; Yi Cheng; Zhigang Wang; Fang Chen; Guorong Zheng
Journal:  PLoS One       Date:  2012-07-03       Impact factor: 3.240

9.  MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1.

Authors:  Y Xu; F Zhao; Z Wang; Y Song; Y Luo; X Zhang; L Jiang; Z Sun; Z Miao; H Xu
Journal:  Oncogene       Date:  2011-08-08       Impact factor: 9.867

Review 10.  DNA methyltransferases: a novel target for prevention and therapy.

Authors:  Dharmalingam Subramaniam; Ravi Thombre; Animesh Dhar; Shrikant Anant
Journal:  Front Oncol       Date:  2014-05-01       Impact factor: 6.244

View more
  25 in total

1.  miR-335 directly, while miR-34a indirectly modulate survivin expression and regulate growth, apoptosis, and invasion of gastric cancer cells.

Authors:  Bairen Yang; Jun Huang; Hao Liu; Weichang Guo; Guoxin Li
Journal:  Tumour Biol       Date:  2015-08-29

Review 2.  Understanding the CREB1-miRNA feedback loop in human malignancies.

Authors:  Ya-Wen Wang; Xu Chen; Rong Ma; Peng Gao
Journal:  Tumour Biol       Date:  2016-04-09

3.  MicroRNA-212 functions as an epigenetic-silenced tumor suppressor involving in tumor metastasis and invasion of gastric cancer through down-regulating PXN expression.

Authors:  Daojiang Li; Zhengrong Li; Jianbo Xiong; Binbin Gong; Guoyang Zhang; Chao Cao; Zhigang Jie; Yi Liu; Yi Cao; Yufeng Yan; Hong Xiong; Lingyu Qiu; Miantian Yang; Hongping Chen; Shuping Jiang; Xiongwen Yang; Heping Chen
Journal:  Am J Cancer Res       Date:  2015-09-15       Impact factor: 6.166

4.  RNA-binding protein QKI-5 inhibits the proliferation of clear cell renal cell carcinoma via post-transcriptional stabilization of RASA1 mRNA.

Authors:  Rui-Li Zhang; Jun-Ping Yang; Li-Xia Peng; Li-Sheng Zheng; Ping Xie; Meng-Yao Wang; Yun Cao; Zhi-Ling Zhang; Fang-Jian Zhou; Chao-Nan Qian; Yong-Xing Bao
Journal:  Cell Cycle       Date:  2016-10-21       Impact factor: 4.534

5.  Comparative analysis of the interaction of HSPs in dendritic cells, macrophages, RGM-1 cells infected by Helicobacter pylori.

Authors:  Yongliang Yao; Jianhong Wu; Tao Gu; Yang Cheng; Guangxin Li
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

6.  Identification of HRAS as cancer-promoting gene in gastric carcinoma cell aggressiveness.

Authors:  Xiao Yu Wu; Wen Tao Liu; Zhen Feng Wu; Che Chen; Jia Yun Liu; Guan Nan Wu; Xue Quan Yao; Fu Kun Liu; Gang Li
Journal:  Am J Cancer Res       Date:  2016-09-01       Impact factor: 6.166

7.  miR-485-5p acts as a negative regulator in gastric cancer progression by targeting flotillin-1.

Authors:  Min Kang; Mei-Ping Ren; Lei Zhao; Chang-Ping Li; Ming-Ming Deng
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

Review 8.  Diverse roles of miR-335 in development and progression of cancers.

Authors:  Long-Ji Luo; Dan-Dan Wang; Jing Wang; Fan Yang; Jin-Hai Tang
Journal:  Tumour Biol       Date:  2016-10-08

Review 9.  Dysregulation of non-coding RNAs in gastric cancer.

Authors:  Qing Yang; Ren-Wen Zhang; Peng-Cheng Sui; Hai-Tao He; Lei Ding
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 10.  The genomic architecture of metastasis in breast cancer: focus on mechanistic aspects, signalling pathways and therapeutic strategies.

Authors:  Yogita Chhichholiya; Prabhat Suman; Sandeep Singh; Anjana Munshi
Journal:  Med Oncol       Date:  2021-07-16       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.